New pill shows promise for Hard-to-Treat blood cancers
NCT ID NCT03913949
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing an experimental oral drug called APG-2575 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to check the drug's safety and find the best dose. About 74 participants will take the drug daily in 28-day cycles. This is a Phase 1 study, so it is primarily looking at safety and how the body processes the drug, not yet whether it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
APG-2575 (an experimental oral drug)
What this could lead to
If successful, this could lead to a new treatment option for people with certain blood cancers that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 74 participants, focused on safety and dosing. The drug may not prove effective or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Procincial hospital
Hefei, Anhui, China
-
Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
-
Henan Provincial Oncology Hospital
Zhengzhou, Henan, China
-
The First Affiliated Hospital, Zhejiang University School of Medicin
Hangzhou, Zhejiang, China
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China